Advances in therapeutics for neurodegenerative tauopathies: Moving toward the specific targeting of the most toxic tau species

J.E. Gerson, D.L. Castillo-Carranza, R. Kayed

Research output: Contribution to journalReview articlepeer-review

64 Citations (Scopus)

Abstract

Neurodegenerative disease is one of the greatest health concerns today and with no effective treatment in sight, it is crucial that researchers find a safe and successful therapeutic. While neurofibrillary tangles are considered the primary tauopathy hallmark, more evidence continues to come to light to suggest that soluble, intermediate tau aggregates - tau oligomers - are the most toxic species in disease. These intermediate tau species may also be responsible for the spread of pathology, suggesting that oligomeric tau may be the best therapeutic target. Here, we summarize results for the modulation of tau by molecular chaperones, small molecules and aggregation inhibitors, post-translational modifications, immunotherapy, other techniques, and future directions. (Figure Presented).

Original languageEnglish
Pages (from-to)752-769
Number of pages18
JournalACS Chemical Neuroscience
Volume5
Issue number9
DOIs
Publication statusPublished - 17 Sept 2014
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2014 American Chemical Society.

Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Fingerprint

Dive into the research topics of 'Advances in therapeutics for neurodegenerative tauopathies: Moving toward the specific targeting of the most toxic tau species'. Together they form a unique fingerprint.

Cite this